Literature DB >> 10981061

The kidney as a target of hypertension.

S Ljungman1.   

Abstract

In spite of improvement in blood pressure control during the last decades, the incidence of hypertension-related end-stage renal disease (ESRD) is reported to have increased and has become a common cause of renal failure, especially in the United States, but also in several other countries. The clinical diagnosis of hypertensive nephrosclerosis is usually presumptive, and an important differential diagnosis in older hypertensive persons is atheromatous renal vascular disease. Many studies of renal function in treated essential hypertension have shown a small and clinically insignificant decline in glomerular filtration rate (GFR). Recent long-term studies indicate that the change in GFR may be nonlinear, with a greater fall in GFR after initiation of antihypertensive treatment, followed by a phase of minimal or normal loss of GFR. There are no available prospective studies indicating that well-treated essential hypertension leads to renal failure, but there are new data indicating that patients with nonmalignant essential hypertension without any underlying renal disease and with early and good blood pressure control do not develop renal failure.

Entities:  

Mesh:

Year:  1999        PMID: 10981061     DOI: 10.1007/s11906-999-0014-9

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  37 in total

1.  Excerpts from the United States Renal Data System 1998 Annual Data Report.

Authors: 
Journal:  Am J Kidney Dis       Date:  1998-08       Impact factor: 8.860

2.  Renal rehabilitation--where are the data?

Authors:  D Rennie
Journal:  N Engl J Med       Date:  1981-02-05       Impact factor: 91.245

Review 3.  Ischemic renal disease: an emerging cause of chronic renal failure and end-stage renal disease.

Authors:  R A Preston; M Epstein
Journal:  J Hypertens       Date:  1997-12       Impact factor: 4.844

4.  Accuracy of the diagnosis of hypertensive nephrosclerosis in African Americans: a report from the African American Study of Kidney Disease (AASK) Trial. AASK Pilot Study Investigators.

Authors:  A Fogo; J A Breyer; M C Smith; W H Cleveland; L Agodoa; K A Kirk; R Glassock
Journal:  Kidney Int       Date:  1997-01       Impact factor: 10.612

Review 5.  Hypertension-related renal injury: a major contributor to end-stage renal disease.

Authors:  W G Walker
Journal:  Am J Kidney Dis       Date:  1993-07       Impact factor: 8.860

6.  Renal function during antihypertensive treatment.

Authors:  S Madhavan; D Stockwell; H Cohen; M H Alderman
Journal:  Lancet       Date:  1995-03-25       Impact factor: 79.321

7.  Early predictors of 15-year end-stage renal disease in hypertensive patients.

Authors:  H M Perry; J P Miller; J R Fornoff; J D Baty; M P Sambhi; G Rutan; D W Moskowitz; S E Carmody
Journal:  Hypertension       Date:  1995-04       Impact factor: 10.190

8.  Renal function change in hypertensive members of the Multiple Risk Factor Intervention Trial. Racial and treatment effects. The MRFIT Research Group.

Authors:  W G Walker; J D Neaton; J A Cutler; R Neuwirth; J D Cohen
Journal:  JAMA       Date:  1992-12-02       Impact factor: 56.272

9.  Does an adequate control of blood pressure protect the kidney in essential hypertension?

Authors:  L M Ruilope; J M Alcazar; E Hernandez; F Moreno; M A Martinez; J L Rodicio
Journal:  J Hypertens       Date:  1990-06       Impact factor: 4.844

10.  Long-term effects of antihypertensive agents on proteinuria and renal function.

Authors:  D D Maki; J Z Ma; T A Louis; B L Kasiske
Journal:  Arch Intern Med       Date:  1995-05-22
View more
  2 in total

1.  Acute and chronic acetaminophen use and renal disease: a case-control study using pharmacy and medical claims.

Authors:  Mugdha Kelkar; Mario A Cleves; Howell R Foster; William R Hogan; Laura P James; Bradley C Martin
Journal:  J Manag Care Pharm       Date:  2012-04

2.  Light to moderate drinking and therapeutic doses of acetaminophen: An assessment of risks for renal dysfunction.

Authors:  Harrison Ndetan; Marion W Evans; Ashwani K Singal; Lane J Brunner; Kirk Calhoun; Karan P Singh
Journal:  Prev Med Rep       Date:  2018-10-24
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.